Standard BioTools Inc. (NASDAQ:LAB) Short Interest Update

Posted by Brenda Bartman on Jul 31st, 2026

Standard BioTools Inc. (NASDAQ:LAB – Get Free Report) was the target of a significant drop in short interest in the month of July. As of July 15th, there was short interest totaling 2,213,551 shares, a drop of 35.4% from the June 30th total of 3,425,003 shares. Based on an average trading volume of 3,059,750 shares, the short-interest ratio is currently 0.7 days. Approximately 0.8% of the company’s stock are sold short.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Staley Capital Advisers Inc. acquired a new stake in shares of Standard BioTools in the first quarter valued at approximately $581,000. Casdin Capital LLC grew its position in Standard BioTools by 14.5% during the fourth quarter. Casdin Capital LLC now owns 88,783,856 shares of the company’s stock worth $113,643,000 after buying an additional 11,225,000 shares in the last quarter. AQR Capital Management LLC increased its stake in Standard BioTools by 862.2% during the 1st quarter. AQR Capital Management LLC now owns 482,912 shares of the company’s stock worth $522,000 after acquiring an additional 432,725 shares during the period. Wells Fargo & Company MN increased its stake in Standard BioTools by 43.1% during the 4th quarter. Wells Fargo & Company MN now owns 347,720 shares of the company’s stock worth $445,000 after acquiring an additional 104,758 shares during the period. Finally, Legal & General Group Plc raised its holdings in Standard BioTools by 25.7% in the 2nd quarter. Legal & General Group Plc now owns 310,435 shares of the company’s stock valued at $373,000 after acquiring an additional 63,484 shares in the last quarter. Institutional investors own 53.74% of the company’s stock.

Standard BioTools Trading Down 3.7%

NASDAQ:LAB traded down $0.03 on Friday, hitting $0.86. The company’s stock had a trading volume of 1,155,495 shares, compared to its average volume of 2,779,779. Standard BioTools has a one year low of $0.70 and a one year high of $1.72. The firm has a market capitalization of $337.28 million, a P/E ratio of 4.32 and a beta of 1.42. The stock has a fifty day moving average of $0.91 and a two-hundred day moving average of $1.03.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Standard BioTools from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 21st. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus target price of $1.35.

Read Our Latest Report on Standard BioTools

Standard BioTools Company Profile

(Get Free Report)

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.